Slingshot members are tracking this event:

Portola (PTLA) Expects US Launch in August 2017 for Betrixaban in Prevention of VTE in Acute Medically Ill Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on Jun 26 2017: "Even as Portola works to launch Bevyxxa, it’s struggling to get manufacturing up to par on another drug in its pipeline, AndexXa"
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 05, 2017
Occurred Source:
Related Keywords Us Launch, Betrixaban, Vte, Acute Medically Ill Patients